Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?

Molebogeng X. Rangaka; Yohhei Hamada; Ibrahim Abubakar

doi:10.1016/S2213-2600(22)00123-0

Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?

Molebogeng X. Rangaka, Yohhei Hamada, Ibrahim Abubakar

Research output: Contribution to journal › Comment/debate

4 Citations (Scopus)

Original language	English
Pages (from-to)	529-531
Number of pages	3
Journal	The Lancet Respiratory Medicine
Volume	10
Issue number	6
DOIs	https://doi.org/10.1016/S2213-2600(22)00123-0
Publication status	Published - Jun 2022
Externally published	Yes

Bibliographical note

Funding Information:
MXR is the recipient of a Wellcome Trust Investigator Award on tuberculosis and diabetes. IA is the recipient of an EU funded award to End-VOC (End SARS-CoV-2 variants of concern). The authors declare no other competing interests.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-2600(22)00123-0

Cite this

@article{b1350cd72acb4a8a903989265fea598b,

title = "Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?",

author = "Rangaka, {Molebogeng X.} and Yohhei Hamada and Ibrahim Abubakar",

note = "Funding Information: MXR is the recipient of a Wellcome Trust Investigator Award on tuberculosis and diabetes. IA is the recipient of an EU funded award to End-VOC (End SARS-CoV-2 variants of concern). The authors declare no other competing interests.",

year = "2022",

month = jun,

doi = "10.1016/S2213-2600(22)00123-0",

language = "English",

volume = "10",

pages = "529--531",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Ltd.",

number = "6",

}

TY - JOUR

T1 - Ending the tuberculosis syndemic

T2 - is COVID-19 the (in)convenient scapegoat for poor progress?

AU - Rangaka, Molebogeng X.

AU - Hamada, Yohhei

AU - Abubakar, Ibrahim

N1 - Funding Information: MXR is the recipient of a Wellcome Trust Investigator Award on tuberculosis and diabetes. IA is the recipient of an EU funded award to End-VOC (End SARS-CoV-2 variants of concern). The authors declare no other competing interests.

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85131702312&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(22)00123-0

DO - 10.1016/S2213-2600(22)00123-0

M3 - Comment/debate

C2 - 35338839

AN - SCOPUS:85131702312

SN - 2213-2600

VL - 10

SP - 529

EP - 531

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 6

ER -

Ending the tuberculosis syndemic: is COVID-19 the (in)convenient scapegoat for poor progress?

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this